{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:49:34Z","timestamp":1785437374016,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bbmt.2018.09.032","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T06:18:19Z","timestamp":1539065899000},"page":"505-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Lauren","family":"Veltri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1264-5968","authenticated-orcid":false,"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.09.032_bib0001","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0002","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0003","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0005","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0006","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0007","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2010.1.62","article-title":"Treating the elderly patient with acute myelogenous leukemia","volume":"2010","author":"Luger","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0011","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0012","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","article-title":"A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial","volume":"116","author":"Rollig","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0013","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0014","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0015","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"Boddu","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse","volume":"32","author":"Boddu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0017","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0018","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0019","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.beha.2017.09.004","article-title":"Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia","volume":"30","author":"Appelbaum","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0020","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0022","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/bmt.2016.156","article-title":"Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years)","volume":"51","author":"Pohlen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0023","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.24270","article-title":"Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia","volume":"91","author":"Aoki","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0024","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2017-07-798751","article-title":"Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion","volume":"131","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0026","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ajh.23988","article-title":"The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia","volume":"90","author":"Ouyang","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0027","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/bmt.2014.99","article-title":"Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future","volume":"49","author":"Jaso","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0028","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2016.144253","article-title":"Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia","volume":"102","author":"Oran","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0029","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0031","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.rmed.2006.11.019","article-title":"Lung function testing in the elderlyG\u00c7\u00f6Can we still use FEV1\/FVC<70% as a criterion of COPD?","volume":"101","author":"Medbo","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0032","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0033","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1200\/JCO.2016.69.3143","article-title":"Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study","volume":"35","author":"Ferrat","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0034","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.leu.2403138","article-title":"Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation","volume":"17","author":"Venditti","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0036","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0039","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0041","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1500140","article-title":"High HLA-DP expression and graft-versus-host disease","volume":"373","author":"Petersdorf","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0042","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","article-title":"Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation","volume":"124","author":"Pidala","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.032_bib0043","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood-2013-02-481945","article-title":"Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3\/4\/5 associate with adverse outcomes in hematopoietic stem cell transplantation","volume":"121","author":"Fern\u00e1ndez-Vi\u00f1a","year":"2013","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:24Z","timestamp":1761059124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118305998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1083879118305998"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.032","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}